About Urogen Pharma (NASDAQ:URGN)
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:URGN
CUSIPN/A
Phone972-9770-7601
Debt
Debt-to-Equity RatioN/A
Current Ratio10.59%
Quick Ratio10.55%
Price-To-Earnings
Trailing P/E Ratio-26.72
Forward P/E Ratio-17.82
P/E GrowthN/A
Sales & Book Value
Annual Sales$8.16 million
Price / Sales96.37
Cash FlowN/A
Price / CashN/A
Book Value$4.98 per share
Price / Book11.48
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees33
Outstanding Shares13,750,000
Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions
What is Urogen Pharma's stock symbol?
Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."
How were Urogen Pharma's earnings last quarter?
Urogen Pharma Ltd (NASDAQ:URGN) announced its quarterly earnings results on Thursday, March, 15th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.65) by $0.09. The business earned $0.33 million during the quarter. View Urogen Pharma's Earnings History.
When is Urogen Pharma's next earnings date?
What price target have analysts set for URGN?
7 analysts have issued 12 month price targets for Urogen Pharma's stock. Their predictions range from $25.00 to $75.00. On average, they anticipate Urogen Pharma's share price to reach $50.60 in the next twelve months. View Analyst Ratings for Urogen Pharma.
What are Wall Street analysts saying about Urogen Pharma stock?
Here are some recent quotes from research analysts about Urogen Pharma stock:
- 1. Cowen Inc analysts commented, "URGN presented updates for MitoGel’s Phase 3 OLYMPUS trial (topline data in 2Q18)." (11/15/2017)
- 2. According to Zacks Investment Research, "UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. " (10/18/2017)
Who are some of Urogen Pharma's key competitors?
Some companies that are related to Urogen Pharma include Xencor (XNCR), Innoviva (INVA), Akcea Therapeutics (AKCA), Radius Health (RDUS), Prothena (PRTA), Impax Laboratories (IPXL), Zogenix (ZGNX), Pacira Pharmaceuticals (PCRX), ImmunoGen (IMGN), Immuron (IMRN), Myovant Sciences (MYOV), Theravance Biopharma (TBPH), G1 Therapeutics (GTHX), Apellis Pharmaceuticals (APLS), Endo International (ENDP), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and PTC Therapeutics (PTCT).
Who are Urogen Pharma's key executives?
Urogen Pharma's management team includes the folowing people:
- Arie S. Belldegrun, Chairman of the Board (Age 67)
- Ron Bentsur, Chief Executive Officer, Director (Age 51)
- Gary S. Titus, Chief Financial Officer (Age 57)
- Gil Hakim, President - Israeli Operation (Age 47)
- Chaim Hurvitz, Director (Age 56)
- Ran Nussbaum, Director (Age 44)
- Kathryn E. Falberg, Independent Director (Age 56)
- Stuart Holden M.D., Independent Director (Age 74)
- Pini Orbach Ph.D., Independent Director (Age 52)
When did Urogen Pharma IPO?
(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.
Has Urogen Pharma been receiving favorable news coverage?
Media coverage about URGN stock has been trending somewhat positive recently, Accern reports. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Urogen Pharma earned a daily sentiment score of 0.17 on Accern's scale. They also assigned media coverage about the company an impact score of 45.71 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Urogen Pharma?
Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Urogen Pharma's stock price today?
One share of URGN stock can currently be purchased for approximately $57.19.
How big of a company is Urogen Pharma?
Urogen Pharma has a market capitalization of $832.78 million and generates $8.16 million in revenue each year. The company earns $-20,000,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Urogen Pharma employs 33 workers across the globe.
How can I contact Urogen Pharma?
Urogen Pharma's mailing address is 9 HaTaasiya St, Raanana L3, 4365007. The company can be reached via phone at 972-9770-7601 or via email at [email protected]
MarketBeat Community Rating for Urogen Pharma (URGN)
MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote "Outperform" if you believe URGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe URGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Urogen Pharma (NASDAQ:URGN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Urogen Pharma (NASDAQ URGN) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 50.49%
Urogen Pharma (NASDAQ URGN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/28/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 209,298 | $40.60 | $8,497,498.80 | |  |
(Data available from 1/1/2013 forward)
Urogen Pharma (NASDAQ URGN) News Headlines
| Source: |
|
Urogen Pharma (NASDAQ:URGN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Urogen Pharma (NASDAQ:URGN) Income Statement, Balance Sheet and Cash Flow Statement
Urogen Pharma (NASDAQ URGN) Stock Chart for Friday, April, 20, 2018
Loading chart…
